

of infectious diseases, Hepatitis B, Hepatitis C, tuberculosis, malaria, HIV or influenza.

36. The method as claimed in claim 21 wherein the peptide is AMASTEGNV or LQNLARTI.

37. A peptide selected from AMASTEGNV and LQNLARTI.

38. A vaccine comprising at least one peptide according to claim 17.--

REMARKS

Favorable consideration of this application and entry of the foregoing amendments are respectfully requested.

The specification has been amended to make reference to the parent PCT application.

The claims have been revised to define the invention with additional clarity. Support for the claims can be found throughout the application, including at page 2, line 27, page 6, lines 11 to 13, Example 3 and claim 5 as originally filed.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

LALVANI et al

Serial No. 09/308,725

Filed: May 24, 1999

Title: ASSAY METHOD FOR PEPTIDE SPECIFIC T-CELLS

Assistant Commissioner for Patents
Washington, DC 20231

Sir:



Atty Dkt. 117-310

C# M#

Group Art Unit:

Examiner:

Date: March 7, 2000

RECEIVED

SEP 14 2000
TECH CENTER 1600/2900

RECEIVED

JUN 27 2003

TECH CENTER 1600/2900

PRELIMINARY AMENDMENT

This is a response/amendment/letter in the above-identified application and includes an attachment which is hereby incorporated by reference and the signature below serves as the signature to the attachment in the absence of any other signature thereon.

Fees are attached as calculated below:

Total effective claims after amendment	0	minus highest number		
previously paid for	20	(at least 20) =	0 x \$ 18.00	\$ 0.00
Independent claims after amendment	0	minus highest number		
previously paid for	3	(at least 3) =	0 x \$ 78.00	\$ 0.00
If proper multiple dependent claims now added for first time, add \$260.00 (ignore improper)				\$ 0.00
Petition is hereby made to extend the current due date so as to cover the filing date of this paper and attachment(s) (\$110.00/1 month; \$380.00/2 months; \$870.00/3 months)				\$ 0.00
Terminal disclaimer enclosed, add \$ 110.00				\$ 0.00
First submission after Final Rejection pursuant to 37 CFR 1.129(a) (\$690.00)				\$ 0.00
Second submission after Final Rejection pursuant to 37 CFR 1.129(a) (\$690.00)				\$ 0.00

☐ Please enter the previously unentered , filed

Subtotal \$ 0.00

If "small entity," then enter half (1/2) of subtotal and subtract -\$ 0.00

☐ Statement filed herewith

Rule 56 Information Disclosure Statement Filing Fee (\$240.00) \$ 0.00

Assignment Recording Fee (\$40.00) \$ 0.00

TOTAL FEE ENCLOSED \$ 0.00

The Commissioner is hereby authorized to charge any deficiency in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Account No. 14-1140. A duplicate copy of this sheet is attached.

1100 North Glebe Road, 8th Floor
Arlington, Virginia 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100
MJW:tat

NIXON & VANDERHYE P.C.
By Atty: Mary J. Wilson, Reg. No. 32,955

Signature: Mary J. Wilson

RECEIVED
JUL 0 2003
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

LALVANI et al

Serial No. **09/308,725**

Filed: **May 24, 1999**

Title: **ASSAY METHOD FOR PEPTIDE SPECIFIC T-CELLS**

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

Atty Dkt. **117-310**

C# M#

Group Art Unit:

Examiner:

Date: **March 7, 2000**

RECEIVED
JUL 09 2003
TECH CENTER 1600/2900
REC'D
SER

RECEIVED

JUN 27 2003

TECH CENTER 1600/2900

PRELIMINARY AMENDMENT

This is a response/amendment/letter in the above-identified application and includes an attachment which is hereby incorporated by reference and the signature below serves as the signature to the attachment in the absence of any other signature thereon.

Fees are attached as calculated below:

Total effective claims after amendment	0	minus highest number		
previously paid for	20	(at least 20) =	0 x \$ 18.00	\$ 0.00
Independent claims after amendment	0	minus highest number		
previously paid for	3	(at least 3) =	0 x \$ 78.00	\$ 0.00
If proper multiple dependent claims now added for first time, add \$260.00 (ignore improper)				\$ 0.00
Petition is hereby made to extend the current due date so as to cover the filing date of this paper and attachment(s) (\$110.00/1 month; \$380.00/2 months; \$870.00/3 months)				\$ 0.00
Terminal disclaimer enclosed, add \$ 110.00				\$ 0.00
First submission after Final Rejection pursuant to 37 CFR 1.129(a) (\$690.00)				\$ 0.00
Second submission after Final Rejection pursuant to 37 CFR 1.129(a) (\$690.00)				\$ 0.00

☐ Please enter the previously unentered , filed

Subtotal \$ 0.00

If "small entity," then enter half (1/2) of subtotal and subtract

-\$ 0.00

☐ Statement filed herewith

Rule 56 Information Disclosure Statement Filing Fee (\$240.00)

\$ 0.00

Assignment Recording Fee (\$40.00)

\$ 0.00

TOTAL FEE ENCLOSED \$ 0.00

The Commissioner is hereby authorized to charge any deficiency in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Account No. 14-1140. A duplicate copy of this sheet is attached.

1100 North Glebe Road, 8th Floor
Arlington, Virginia 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100
MJW:tat

NIXON & VANDERHYE P.C.
By Atty: Mary J. Wilson, Reg. No. 32,955

Signature:

